Overview

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Status:
Not yet recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the MTD and/or RP2D of surufatinib administered in combination with gemcitabine in pediatric patients with recurrent or refractory solid tumors or lymphoma. The study will be conducted in 2 parts.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Hutchison Medipharma Limited

Treatments:

Gemcitabine